Company intelligence / Profile preview

Vectura

Chippenham, United Kingdomvecturafertinpharma.com ↗

Ownership: Private
Employees: ~450
Development stage: Commercial

Overview

Vectura is a leading developer of inhaled medicines and drug delivery devices with over 25 years’ experience. Its technologies have contributed to the launch of at least 13 major inhaled medicines through partnerships with global pharmaceutical companies. The company offers end-to-end services from formulation through device design, development, scale-up, clinical manufacturing, and regulatory support. It was acquired by Philip Morris International in 2021 and then by Molex/Phillips Medisize in late 2024.

Therapeutic areas: Pulmonology
Modalities: Small moleculeBiologicComplex combination productDevice
Industry: Contract Manufacturing Organization

Partnerships

GSKNovartis/SandozMundipharma/Kyorin Pharmaceutical Co.Bayer

Beyond the preview

Go deeper on Vectura.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vectura.

Explore the full profile